Study Details
A study to evaluate ASP0367 in participants with primary mitochondrial myopathy
Clinicaltrials.gov ID
Astellas Study ID
0367-CL-1201
EudraCT ID
N/A
Condition
Primary Mitochondrial Myopathy (PMM)
Phase
Phase 2
Age
18 Years - 54 Years
Sex
Female & Male
Product
ASP0367
Type
Interventional
Trial Dates
May 2021 - May 2024
Masking
Triple (Participant, Care Provider, Investigator)
Enrollment number
195
A Randomized, Double-blind, Placebo-controlled Adaptive Phase 2/3 Study with Open-label Extension to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants with Primary Mitochondrial Myopathy
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A study to evaluate ASP0367 in participants with primary mitochondrial myopathy? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Akron Children’s Hospital
Akron, United States, 44308
University of Texas Health Science Center at Hosuton
Houston, United States, 77030
Columbia University Irving Medical Center
New York, United States, 10032
Massachusetts General Hospital
Boston, United States, 02114
Mayo Clinic
Rochester, United States, 55905
Baylor College of Medicine
Houston, United States, 77030
Cleveland Clinic
Cleveland, United States, 44195
Stanford University Medical Center
Stanford, United States, 94305
Mayo Clinic Arizona
Phoenix, United States, 85054
Mayo Clinic Florida
Jacksonville, United States, 32224
Children’s Hospital Colorado
Aurora, United States, 80045
Seattle Children's Hospital
Seattle, United States, 98105
University of California, San Diego
La Jolla, United States, 92093
Children's Hospital of Philadelphia
Philadelphia, United States, 19104